These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 19863869

  • 21. Hydrolysis of minor glycerophospholipids of plasma lipoproteins by human group IIA, V and X secretory phospholipases A2.
    Pruzanski W, Lambeau G, Lazdunski M, Cho W, Kopilov J, Kuksis A.
    Biochim Biophys Acta; 2007 Jan; 1771(1):5-19. PubMed ID: 17197234
    [Abstract] [Full Text] [Related]

  • 22. Novel insights of secretory phospholipase a(2) action in cardiology.
    Fujioka D, Kugiyama K.
    Trends Cardiovasc Med; 2009 Apr; 19(3):100-3. PubMed ID: 19679267
    [Abstract] [Full Text] [Related]

  • 23. Phospholipase A(2) in vascular disease.
    Hurt-Camejo E, Camejo G, Peilot H, Oörni K, Kovanen P.
    Circ Res; 2001 Aug 17; 89(4):298-304. PubMed ID: 11509445
    [Abstract] [Full Text] [Related]

  • 24. Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.
    Titsworth WL, Liu NK, Xu XM.
    CNS Neurol Disord Drug Targets; 2008 Jun 17; 7(3):254-69. PubMed ID: 18673210
    [Abstract] [Full Text] [Related]

  • 25. Mitogenic effect of lipoproteins on human vascular smooth muscle cells: the impact of hydrolysis by gr II A phospholipase A(2).
    Pruzanski W, Stefanski E, Kopilov J, Kuksis A.
    Lab Invest; 2001 May 17; 81(5):757-65. PubMed ID: 11351047
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Reductions of phospholipase A(2) inhibition of pulmonary surfactant with hyaluronan.
    Iwanicki JL, Lu KW, Taeusch HW.
    Exp Lung Res; 2010 Apr 17; 36(3):167-74. PubMed ID: 20334607
    [Abstract] [Full Text] [Related]

  • 29. Differences between group X and group V secretory phospholipase A(2) in lipolytic modification of lipoproteins.
    Kamitani S, Yamada K, Yamamoto S, Ishimoto Y, Ono T, Saiga A, Hanasaki K.
    Cell Mol Biol Lett; 2012 Sep 17; 17(3):459-78. PubMed ID: 22706677
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?
    Divchev D, Schieffer B.
    Vasc Health Risk Manag; 2008 Sep 17; 4(3):597-604. PubMed ID: 18827909
    [Abstract] [Full Text] [Related]

  • 33. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
    Shaposhnik Z, Wang X, Trias J, Fraser H, Lusis AJ.
    J Lipid Res; 2009 Apr 17; 50(4):623-9. PubMed ID: 19029066
    [Abstract] [Full Text] [Related]

  • 34. Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
    Rosenson RS, Fraser H, Goulder MA, Hislop C.
    Cardiovasc Drugs Ther; 2011 Dec 17; 25(6):539-44. PubMed ID: 21989792
    [Abstract] [Full Text] [Related]

  • 35. Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice.
    Murakami M, Taketomi Y, Girard C, Yamamoto K, Lambeau G.
    Biochimie; 2010 Jun 17; 92(6):561-82. PubMed ID: 20347923
    [Abstract] [Full Text] [Related]

  • 36. Secretory phospholipase A2 enzymes in atherogenesis.
    Webb NR.
    Curr Opin Lipidol; 2005 Jun 17; 16(3):341-4. PubMed ID: 15891396
    [Abstract] [Full Text] [Related]

  • 37. Opposite effects of native and oxidized lipoproteins on the activity of secretory phospholipase A(2) group IIA.
    Korotaeva AA, Samoilova EV, Pirkova AA, Ameliushkina VA, Prokazova NV, Tkachuk VA, Chazov EI.
    Prostaglandins Other Lipid Mediat; 2009 Nov 17; 90(1-2):37-41. PubMed ID: 19647092
    [Abstract] [Full Text] [Related]

  • 38. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.
    Ivandic B, Castellani LW, Wang XP, Qiao JH, Mehrabian M, Navab M, Fogelman AM, Grass DS, Swanson ME, de Beer MC, de Beer F, Lusis AJ.
    Arterioscler Thromb Vasc Biol; 1999 May 17; 19(5):1284-90. PubMed ID: 10323781
    [Abstract] [Full Text] [Related]

  • 39. The capacity of group V sPLA2 to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo.
    Boyanovsky B, Zack M, Forrest K, Webb NR.
    Arterioscler Thromb Vasc Biol; 2009 Apr 17; 29(4):532-8. PubMed ID: 19164803
    [Abstract] [Full Text] [Related]

  • 40. Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology.
    Curfs DM, Ghesquiere SA, Vergouwe MN, van der Made I, Gijbels MJ, Greaves DR, Verbeek JS, Hofker MH, de Winther MP.
    J Biol Chem; 2008 Aug 01; 283(31):21640-8. PubMed ID: 18511424
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.